Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharma focused on cystic fibrosis, will participate in two June 2026 investor conferences.

Rhea-AI Summary

Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharma focused on cystic fibrosis, will participate in two June 2026 investor conferences.

Management presents at the Jefferies Global Healthcare Conference on June 3, 2026, at 12:15 p.m. ET and a Goldman Sachs Global Healthcare fireside chat on June 10, 2026, at 10:00 a.m. ET. Live webcasts and replays will be available in the company’s Investors section online.

Argus May 27 session

+1.28% close to close Open Argus

Details

News Market Reaction – SION

On May 27, the day this news came out, SION closed 1.28% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Market Context

This announcement signals continued investor-relations activity, with June 2026 appearances at major...

Analysis

This announcement signals continued investor-relations activity, with June 2026 appearances at major healthcare conferences providing forums to discuss cystic fibrosis programs and strategy. Recent history shows meaningful stock moves around earnings and clinical milestones, while conference news has generally produced modest reactions. Investors may watch upcoming topline data timing, use of the $250,000,000 ATM capacity, and expense trends from recent filings as the more material drivers beyond this scheduling update.

Key Figures

Jefferies conference date: June 3, 2026 Jefferies presentation time: 12:15 p.m. ET Goldman Sachs conference date: June 10, 2026 +2 more

Jefferies conference date

June 3, 2026

Jefferies Global Healthcare Conference presentation date

Jefferies presentation time

12:15 p.m. ET

Scheduled time for Jefferies conference presentation

Goldman Sachs conference date

June 10, 2026

Goldman Sachs 47th Annual Global Healthcare Conference fireside chat

Goldman Sachs event time

10:00 a.m. ET

Scheduled time for Goldman Sachs fireside chat

Goldman Sachs conference edition

47th Annual

Edition number of Goldman Sachs Global Healthcare Conference

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Investor conference participation

   24h Move

   +5.3%

   Announced participation in 2026 RBC Capital Markets healthcare conference.

2. May 12

   Quarterly earnings update

   24h Move

   -10.9%

   Reported Q1 2026 results with higher R&D, G&A and net loss.

3. Apr 27

   Clinical trial milestone

   24h Move

   +2.9%

   Completed enrollment in PreciSION CF Phase 2a trial of SION-719.

4. Apr 07

   Investor meetings announcement

   24h Move

   -1.7%

   Planned one-on-one investor meetings at Raymond James biotech symposium.

5. Mar 02

   Earnings and pipeline update

   24h Move

   -7.2%

   Reported Q4/FY 2025 results with higher net loss and expenses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cystic fibrosis

1 terms

cystic fibrosis medical

"to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced"

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:

• 2026 Jefferies Global Healthcare Conference presentation on Wednesday, June 3^rd, 2026, at 12:15 p.m. ET; and
• Goldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat on Wednesday, June 10^th, 2026, at 10:00 a.m. ET

Live webcasts can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com. Replays will also be available following the events.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact 
Sarah Spencer
media@sionnatx.com

Investor Contact 
Juliet Labadorf 
ir@sionnatx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Sionna Therapeutics (SION) present at the Jefferies Global Healthcare Conference 2026?

Sionna Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 12:15 p.m. ET. According to Sionna, investors can access the live webcast via the company’s Investors website section.

What is the schedule for Sionna Therapeutics (SION) at the Goldman Sachs Global Healthcare Conference 2026?

Sionna Therapeutics will host a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:00 a.m. ET. According to Sionna, the event will be webcast live for investors.

How can investors access the June 2026 Sionna Therapeutics (SION) conference webcasts?

Investors can access live webcasts of Sionna’s June 2026 conference events through the Investors section of its website. According to Sionna, webcast replays will also be made available after the events conclude.

Will replays of Sionna Therapeutics (SION) June 2026 investor conferences be available?

Yes, replays of Sionna Therapeutics’ June 2026 investor presentations will be available. According to Sionna, investors can find these replays in the Investors section of the company’s website following each event.

What type of company is Sionna Therapeutics (SION) participating in June 2026 conferences?

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment. According to Sionna, the company aims to revolutionize the current treatment paradigm and will discuss its progress at upcoming June 2026 investor events.

Why are the June 2026 investor conferences important for Sionna Therapeutics (SION) shareholders?

The June 2026 investor conferences give shareholders direct insight into Sionna’s strategy and clinical focus. According to Sionna, management’s presentations and fireside chat will be accessible via webcast, supporting transparency and ongoing investor communication.